Increased serum adiponectin concentrations in amenorrheic physically active women are associated with impaired bone health but not with estrogen exposure.

This item was submitted to Loughborough University's Institutional Repository by the/an author.

Citation: O’DONNELL, E. and DE SOUZA, M.J., 2011. Increased serum adiponectin concentrations in amenorrheic physically active women are associated with impaired bone health but not with estrogen exposure. Bone, 48(4), pp. 760-767.

Additional Information:

- This paper was accepted for publication in the journal Bone and the definitive published version is available at: http://dx.doi.org/10.1016/j.bone.2010.12.018

Metadata Record: https://dspace.lboro.ac.uk/2134/20630

Version: Accepted for publication

Publisher: © Elsevier

Rights: This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/

Please cite the published version.
Increased Serum Adiponectin Concentrations in Amenorrheic Physically Active Women are Associated with Impaired Bone Health but not with Estrogen Exposure

Emma O’Donnell1,2 and Mary Jane De Souza3

1Cardiovascular Research Laboratory, 2Women’s Exercise and Bone Health Laboratory, Department of Exercise Sciences, University of Toronto, Toronto, Ontario, M5S 2W6, Canada; 3Women’s Health and Exercise Laboratory, Department of Kinesiology, Pennsylvania State University, 104 Noll Laboratory, University Park, PA, 16803, USA.

Corresponding Author:
Mary Jane De Souza, Ph.D., FACSM, Women’s Health and Exercise Laboratory, Department of Kinesiology, The Pennsylvania State University, 104 Noll Laboratory, University Park, PA 16803. Tel: 814-863-0045, Fax: 814-865-4602, Email: mjd34@psu.edu

Key terms: adipokines, adipose tissue, amenorrhea, bone, exercise

Abbreviated Title: Adiponectin in Amenorrheic Athletes
Abstract

Background: The role of adiponectin in mediating gonadal status and bone health in weight-stable healthy adult female athletes with secondary amenorrhea has not yet been described.

Methods: Using a prospective observational study, age matched premenopausal women were studied, including: 1) sedentary ovulatory women (SedOv; n=10), 2) exercising ovulatory women (ExOv; n=15), and 3) exercising amenorrheic women (ExAmen; n=9). Primary outcome measures included serum total adiponectin and daily urinary estrogen (E1G) levels, expressed as area under the curve (AUC), body fat distribution, and bone mineral density (BMD). Serum leptin, ghrelin, total triiodothyronine (TT3), insulin, and resting energy expenditure (REE) were also determined.

Results: The women in this study did not differ in age (25.3±1.4 years; mean ± SEM), height (164±1 cm), weight (57.7±1.0 kg) and BMI (21.5±0.4 kg/m²). Exercising women had a higher fat free mass (FFM), lower fat mass (FM) and lower serum leptin concentrations (p<0.05) compared to sedentary women. Adiponectin and ghrelin levels were higher (p<0.05), and TT3 (p=0.019), urinary E1G AUC (p=0.002) lower in ExAmen compared with ExOv and SedOv. Total and L1-L4 BMD were lower (p<0.05) in ExAmen compared with ExOv. Stepwise linear regression identified trunkal FM as the strongest predictor of log adiponectin adjusted for FM (F=23.54, p<0.001). L1-L4 BMD was predicted by log adiponectin and E1G AUC (F=9.856, p=0.045). Total BMD was predicted by log adiponectin (F=7.948, p=0.009). TT3 was the strongest predictor of E1G AUC (F=9.885, p=0.004).

Conclusions: Hypoestrogenic adult female athletes with secondary amenorrhea demonstrate elevated circulating adiponectin relative to FM in association with impaired bone health. Estrogen exposure was predicted by TT3, but not adiponectin. These findings suggest that nutritionally regulated hormones may mediate gonadal status, and that adiponectin and estrogen, either
independently or in combination, may mediate bone health in adult amenorrheic physically active
women.
1. INTRODUCTION

In exercising women, energy deficiency, a consequence of inadequate caloric intake relative to exercise energy expenditure, has been proposed as the causal mechanism of menstrual disturbances [1, 2]. While not all exercising women experience symptomatic menstrual disturbances, between 2-44 % of female athletes have reported amenorrhea, the most severe menstrual disorder [3, 4]. Secondary to inadequate caloric intake, energy deficient amenorrheic athletes demonstrate hypoestrogenemia and a hypometabolic state, including suppressed concentrations of glucose, leptin, insulin, and total triiodothyronine (TT3) and elevated levels of ghrelin and peptide YY [5-10]. In adolescent amenorrheic athletes, elevated ghrelin and reduced leptin concentrations predict suppressed levels of gonadal steroids [8]. It is not known if these, or other factors, such as adiponectin, similarly predict gonadal status in adult amenorrheic athletes.

Adiponectin is an adipose tissue-specific secretory protein that is expressed exclusively in differentiated adipocytes [11]. In contrast to other adipokines, such as tumor-necrosis factor and interleukin-6, which are upregulated with increasing adiposity, adiponectin concentrations correlate negatively with obesity and insulin resistance [12, 13]. Conversely, adiponectin concentrations have been reported to correlate both positively [14] and negatively [15] with low body weight, i.e., anorexia nervosa. Reasons for discrepancy in anorexia nervosa are unclear, but may be related, in part to body-fat distribution. For example, recent in vitro evidence demonstrates that the rate of adiponectin secretion is approximately threefold higher from visceral compared with subcutaneous fat, suggesting that distribution of body fat rather than total fat amount may be important [16]. Examination of possible relationships between fat-deposition site and circulating adiponectin concentrations in premenopausal eumenorrheic and amenorrheic women has not yet been reported.

The regulatory role and consequences of altered adiponectin metabolism are not yet well described. Studies indicate, however, that metabolic rate may be increased and bone health impaired by hypo- and hyper-adiponectinemia, respectively [14, 17]. Several studies have also
demonstrated that women have higher adiponectin levels compared to men, independent of body fat mass or body fat distribution [13, 18], suggesting that circulating gonadal steroids may affect adiponectin secretion [19]. To date, however, there have been no reports describing whether estrogen exposure, as assessed by daily urinary analysis of ovarian steroids over time, is mediated by nutritionally regulated hormones, such as adiponectin, in young adult physically active amenorrheic women. Such assessment may increase the ability to detect estrogenic associations, when present, compared with one-time sample serum measures of estradiol.

The objectives of the current study were threefold. In eumenorrheic ovulatory athletes and amenorrheic athletes, to explore: 1) the relationship between adiponectin concentrations and gonadal status (i.e., estrogen exposure) as assessed via daily urinary measures over time; 2) the relationship between adiponectin and nutritionally mediated factors known to be altered in response to energy deficiency, including TT3 and resting energy expenditure; and 3) the associations between adiponectin, body composition, body fat distribution and bone health. We hypothesized that compared to estrogen replete women, hypoestrogenic physically active adult premenopausal women with energy deficiency associated amenorrhea (EDAA) would demonstrate elevated serum adiponectin concentrations, and that these concentrations would predict gonadal status and bone health. We further postulated that adiponectin concentrations would be negatively associated with nutritionally mediated factors known to be altered in response to energy deficiency. Finally, we hypothesized that central (i.e., visceral) adipose mass would demonstrate stronger associations with adiponectin compared with peripheral (i.e., subcutaneous) adipose deposition.

2. METHODOLOGY

2.1 Participants

Participants were recruited by posters. Physical activity status was required to have been consistent for the previous 6 months. Eligibility criteria for the study included: 1) age 18 to 35
yrs; 2) good health determined by a medical exam; 3) no chronic illness, including hyperprolactinemia, polycystic ovarian syndrome, and thyroid disease; 4) stable self reported menstrual status (i.e., same menstrual status) over the preceding 3 months, with menstruating women having cycle lengths between 25-35 days, and athletic women with secondary amenorrhea having not menstruated for at least 90 consecutive days [4]; 5) non-smoking; 6) not currently dieting and weight stable for the preceding 3 months, as determined by self-report; 7) absence of hormonal therapy for at least 12 months; 8) no history or current clinical diagnosis of eating disorders and 9) no other contraindications that would preclude participation in the study.

The study was approved by the institutional committee on human research by the Ethics Review Board at the University of Toronto, and confirmed to the standards set by the latest revision of the Declaration of Helsinki. All volunteers signed an approved informed consent document.

### 2.2 Experimental Design

We originally conducted a prospective observational study on a rolling basis over 2-3 years to examine relationships between physical activity, metabolism, cardiovascular health and reproductive function. Fifty-two women completed the entire study, with 34 of these 52 being included in the current post-hoc study. The relationship between estrogen exposure and numerous metabolic and nutritionally regulated hormones on cardiovascular function in a subset of these women have previously been described by our laboratory [6, 20]. However, the potential for nutritionally regulated hormones, specifically adiponectin, and indices of metabolic status, namely TT3 and REE, to predict gonadal status has not been previously reported by our group.

### 2.3 Observational Time Periods

Menstruating women were monitored for 2 to 3 consecutive menstrual cycles, and amenorrheic women were monitored for 2 to 3 consecutive 30-day monitoring periods. All measures, except urinary measures which were assessed daily, were obtained during the early
follicular phase (days 2-6) across two-to three menstrual cycles for menstruating women, and
during days 1-6 of each 30-day monitoring period for amenorrheic women. The mean of these
measures were used in statistical analyses.

2.4 Exercise and Menstrual Status

Exercise status was defined as “sedentary” when purposeful exercise was less than 2
hours per week and “exercising” when purposeful exercise was more than 2 hours per week [21].
Purposeful exercise, defined as exercise that elicited a heart rate (HR) greater than 55% of
maximal HR (220 minus age) for 3 minutes or more, was documented in exercise logs [6]. HR
was determined by the subject counting heart beats during a 10 second period of carotid artery
palpation after each exercise bout. In conjunction with the hours of exercise activity criterion, we
also utilized a VO₂ max of <40 ml/kg/min to reflect sedentary status and 40 ml/kg/min or greater
to reflect exercising status consistent with published data of this parameter [22].

Menstrual status was determined from daily first morning void urine samples collected by
all participants for the duration of the study period. Urine samples were assayed for luteinizing
hormone (LH), pregnanediol 3-glucuronide (PdG), and estrone 3-glucuronide (E1G) to assess
ovulatory status and estrogen exposure. Our group has previously detailed the criteria for
detection of positive ovulation and menstrual status [6].

2.5 Estrogen Exposure

Calculation of estrogen exposure over time has been described, in detail, elsewhere [6].
Briefly, using daily urinary estrogen levels, estrogen exposure over time was calculated by the
trapezoidal area under the curve method across two to three menstrual cycles for menstruating
women, and across two to three 30-day monitoring periods for amenorrheic women.
2.6 Study Groups

Three groupings were retrospectively established based on exercise and menstrual status:
1) sedentary women with ovulatory menstrual cycles (SedOv; n=10), 2) exercising women with
ovulatory menstrual cycles (ExOv; n=15), and 3) exercising women with amenorrhea, defined as
cessation of menses for >90 d (ExAmen; n=9) [23].

2.7 Anthropometric Measures

Average total body mass was determined from weekly measures to the nearest 0.1 kg on
a physician’s balance scale (Detecto, Webb City, MO). Height was measured to the nearest 1.0
cm at the beginning of the study period. Body mass index (BMI) was calculated (kg/m²).

2.8 Body Composition and Bone Mineral Density

Dual-energy x-ray absorptiometry (DXA) was utilized to determine body composition
and bone mineral density (BMD) once during the study by a trained technician (Prodigy, General
Electric Lunar Corporation, Madison, WI, enCORE 2002 software, version 6.50.069). Whole
body and lumbar (L1-L4) BMD (g/cm²) and Z-scores were determined. Central fat mass (kg) was
determined from the fat mass measured in the trunk, and peripheral fat mass was determined as
the sum of fat mass measured in the arms and legs. BMD (g/cm²) was determined at the spine
(L1–L4) and for total body by an ISCD certified operator. A 28 subject precision study was
performed in premenopausal women and precision was 0.6 and 0.7 % at the total body and
lumbar spine, respectively. The DXA scanner has a precision of < 1% coefficient of variation for
body composition measurements.

2.9 Resting Energy Expenditure

Using the Weir equation [24], REE (kcal day⁻¹) was determined by indirect calorimetry
with a ventilated hood system (SensorMedics Vmax Series, Yorba Linda, CA). After a 45 minute
supine rest period, REE measures were taken for 30 minutes between 0830 and 1100. Oxygen consumption (VO$_2$; mL min$^{-1}$) and carbon dioxide production (VCO$_2$; mL min$^{-1}$) were measured every 20-seconds during REE measurement. To calculate REE, data for VO$_2$ and VCO$_2$ were only used if steady state was attained for a minimum of 10 minutes, and respiratory quotient values did not varying by more than 10%. REE adjusted for fat free mass (FFM) was calculated to adjust metabolic rate for metabolically active tissue (i.e., muscle).

2.10 Peak Aerobic Capacity

VO$_2$ peak was measured once by a progressive treadmill test to volitional exhaustion. Expired gases were collected continuously to measure inspired air volumes and to analyze breath-by-breath samples (Moxus Modular VO$_2$ System, Applied Electrochemistry Inc., Pittsburgh, PA).

2.11 Serum Measures

Serum was analyzed for total adiponectin, leptin, total ghrelin, total triiodothyronine (TT3) and insulin. Eight-hour fasted blood samples were collected between 0730 and 1000 hr. Serum samples were immediately stored at -80°C until analyses were run. Total adiponectin (i.e., low, medium, and high molecular weight) was analyzed using an enzyme immunoassay technique (Quantikine Assay Kit, DRP300, R&D Systems Inc., Minneapolis, MN). Sensitivity was 0.246 ng/mL. Leptin was analyzed using a direct sandwich enzyme-linked immunosorbent assay (ELISA, Linco Research, Inc., St. Charles, MO). Analytical sensitivity was 0.5 ng/mL. Total serum ghrelin was analyzed using radioimmunoassay techniques (Linco research Inc., St Charles, MO). Analytical sensitivity of the ghrelin assay was 2.97 pmol L$^{-1}$. Serum insulin and TT3 were analyzed using a chemiluminescence-based immunoassay analyzer (Immulite, Diagnostics Products Corporation, Los Angeles, CA). Analytical sensitivity for the insulin assay was 13.89 pmol L$^{-1}$, and for the TT3 assay was 0.54 nmol L$^{-1}$. All inter- and intra-assay coefficients of variation have previously been reported by our group [6, 20].
2.12 Urinary Measures

Measures of daily urinary metabolites were determined using microtiter plate competitive enzyme immunoassays to detect pregnanediol 3-glucuronide (PdG), and estrone 3-glucuronide (E1G). Detailed methods for these immunoassays have been described previously [6, 20]. The inter-assay coefficients of variation for high and low internal controls were 14.7% and 13.1% for E1G and 15.68% and 17.7% for PdG. Urine samples were corrected for specific gravity using a hand refractometer (NSG Precision Cells, Inc., Farmingdale, NY) to account for hydration status.

Urinary LH, assessed in ovulatory women only, was determined by double antibody radioimmunoassay (Diagnostic Products Corp., Los Angeles, CA). The sensitivity of the LH assay was 0.6 mIU L\(^{-1}\). The intra-assay and inter-assay coefficients of variation were 1.6% and 7.1%, respectively.

2.13 Statistics

Data screening, conducted prior to statistical analysis included outlier detection, and examination of variable distributions within each of the three groups for normality. No outliers were detected, but adiponectin, leptin and urinary progesterone were determined to be positively skewed and were log transformed to approximate normal distribution. All other data sets were normally distributed. Comparison of data between all three groups were analyzed using one-way ANOVA, and when a significant main (fixed) effect was observed, the least significant squares was used to determine where the significant differences existed. Multiple comparisons were adjusted by using Bonferroni methods. Comparisons between two groups were analyzed using independent samples \(t\)-test. Using pooled data, Pearson’s bivariate correlational analyses were used to determine significant linear independent associations between adiponectin, estrogen exposure, and all other variables of interest. Running separate analyses, mixed model linear regression using stepwise methods (\(P=0.15\) for entry, and \(P=0.20\) to leave the model) were used
to explore predictors of gonadal status, adiponectin levels and bone health. Variables included in
the models were hormones and parameters of body composition of interest to the current study, as
well as those that have been previously shown by others to be associated with each dependent
variable of interest, regardless of whether significant bivariate correlations were observed
between these variables and the dependent variable. This method of inclusion was selected to
account for potential confounding effects of various variables and to rule out the masking of
associations of various independent variables with the dependent variable because of
confounders. Data were analyzed using packaged software (SPSS version 12.0; SPSS Inc.,
Chicago, IL). A significance level of $P<0.05$ was used to detect the differences for statistical
procedures. The mean of 2-3 values for serum adiponectin, leptin, ghrelin, TT3, insulin, and
urinary estrogen and progesterone for each subject were utilized in statistical analyses. All data
are presented as the mean ± SEM.

3. RESULTS

3.1 Participant Characteristics

Participant characteristics are summarized in Table 1. Groups did not differ ($p>0.05$) in
age, height, weight and BMI. All subjects were weight stable throughout the study period. Age
of menarche was similar ($p>0.05$) among all groups, but gynecologic age (chronologic age minus
age of menarche; years) was lowest ($p=0.024$; main effect) in ExAmen (9.5 ± 1.4), compared
with ExOv (12.6 ± 0.9) and SedOv (15.6 ± 1.8) women. Average cycle length was 28.5 ± 0.8 and
28.9 ± 0.7 days in the SedOv and ExOv groups, respectively. Average duration of amenorrhea for
the ExAmen group was 247 ± 48 days. Exercising groups had higher ($p<0.001$; main effect)
cardiorespiratory fitness and lower ($p<0.05$; main effect) percent body fat, and total and central
fat mass (kg) compared with sedentary women. ExAmen trended toward lower ($p=0.054$; main
effect) peripheral fat mass compared with SedOv. REE adjusted for FFM was lower ($p=0.002$;
main effect) in ExAmen compared with all other groups. Total BMD, L1-L4 BMD and L1-L4 Z-score were lower ($p<0.05$; main effect) in ExAmen compared with ExOv.

3.2 Serum Measures

Serum measures are shown in Table 2. Log adiponectin trended toward higher concentrations ($p=0.056$; main effect) in ExAmen compared with SedOv and ExOv women. When log adiponectin was adjusted for fat mass (kg), ExAmen had significantly higher ($p=0.001$; main effect) concentrations compared with all other groups (Figure 1). As previously reported by our group [6, 20], serum leptin concentrations were lower ($p=0.012$; main effect) in exercising women (ExOv, 4.7 ± 0.7 ng/ml; ExAmen, 4.5 ± 1.0 ng/ml; log adjusted values) compared to sedentary women (9.3 ± 1.8 ng/ml). Consistent with our previous data [25], serum ghrelin concentrations (pg/ml) were higher ($p=0.011$; main effect) in ExAmen (1939.7 ± 215.9) compared with SedOv (1385.2 ± 99.7) and ExOv (1397 ± 87.3), and serum TT3 (ng/dl) lower in ExAmen (89.1 ± 8.8), compared with SedOv (111.5 ± 2.7) and ExOv (103.3 ± 3.1). Serum insulin concentrations were similar (4.7 ± 0.3 µIU/ml; pooled value; $p=0.327$; main effect) among the groups.

3.3 Urinary Measures

As previously reported by our group [6, 7] urinary E1G and log PdG exposure (see Table 2), determined by the AUC trapezoidal method, was significantly lower ($p=0.002$ and $p=0.001$ for E1G and log PdG, respectively; main effects) in the ExAmen group compared with ExOv and SedOv groups across the menstrual cycle/monitoring period (Figure 2). E1G UC remained significantly lower in ExAmen after adjusting for fat mass. LH levels, assessed in ovulatory women only, were similar ($p>0.05$) between SedOv and ExOv groups.
3.4 Adiponectin Correlates

Using pooled data (Table 3), we report that regional fat mass (i.e., trunk and peripheral) and total fat mass, percent body fat, log adjusted leptin, ghrelin, TT3, REE adjusted for FFM, insulin and urinary E1G AUC measures are not correlated with log adiponectin in adult physically active and inactive women. Log adiponectin adjusted for fat mass was also not associated with ghrelin, REE adjusted for FFM, TT3, insulin, and urinary E1G AUC. In contrast, both log adiponectin and log adiponectin adjusted for fat mass were positively associated with age at menarche ($r=0.461$, $p=0.006$; $r=0.352$, $p=0.048$; respectively), and negatively associated with gynecologic age ($r=-0.379$, $p=0.027$; $r=-0.489$, $p=0.005$; respectively) and all bone measures (see Table 3). As expected, log leptin was positively associated ($p<0.05$) with all indices of adiposity. In contrast, log adiponectin adjusted for fat mass (kg) was negatively associated ($p<0.05$) with all indices of adiposity.

Examining each group independently, (i.e., SedOv, ExOv, and ExAmen), serum log adiponectin was not associated ($p>0.05$) with urinary E1G AUC, age, age at menarche, gynecologic age, insulin, ghrelin, TT3, REE adjusted for FFM, log leptin or measures of body fat in any group. In ExOv only, log adiponectin was inversely associated ($p<0.05$) with all bone measures, except total BMD ($p=0.130$). For log adiponectin adjusted for fat mass, SedOv group only demonstrated negative associations with most measures of fat mass, including percent body fat ($r=-0.730$, $p=0.026$), central fat mass ($r=-0.755$, $p=0.019$), total fat mass ($r=-0.741$, $p=0.022$), and BMI ($r=-0.799$, $p=0.010$). In ExAmen only, urinary E1G AUC trended toward a positive association with log adiponectin adjusted for fat mass ($r=0.657$, $p=0.077$).

3.5 Predictors of Adiponectin

Using pooled data for stepwise linear regression, we entered variables that have been previously reported to be associated with adiponectin, including leptin, ghrelin, fat mass, BMI, and nutritional status [8, 14, 17, 26]. Specifically, variables in the regression model included:
BMI, log leptin, ghrelin, TT3, and central and peripheral fat mass. Both fat mass measures were included in the model to determine whether site specific body fat deposition predicted adiponectin levels. No predictors of log adiponectin were identified. In contrast, fat mass adjusted log adiponectin was predicted solely by trunkal fat mass (see Table 4), which explained \(~41\%\) of the variance (adjusted \(R^2=0.413, p<0.001\)). Variables included in this model were the same as that for log adiponectin.

### 3.6 Associations with, and Predictors of, Gonadal Status

Using pooled data for bivariate analyses, nutritionally mediated metabolic indicators of energy deficiency, such as TT3 and REE adjusted for FFM, were independently and positively associated with E1G AUC in the current study (\(r= 0.463, p=0.007\); \(r= 0.389, p=0.030\), respectively). In contrast, log leptin, ghrelin, and regional and total fat mass were not associated with E1G AUC. Urinary log PdG AUC demonstrated positive associations with E1G AUC (\(r=0.575, p=0.001\)) and TT3 (\(r=0.419, p=0.014\)). LH levels, assessed in ovulatory women only, did not correlate with any hormonal, nutritional, body compositional or bone health measures when analyzed using SedOv and ExOv women only.

Due to detection of fewer significant correlates for PdG AUC or LH compared with E1G AUC, linear regression models for predictors of gonadal status focused on E1G AUC. Using pooled data for stepwise linear regression, we entered variables of interest, namely adiponectin, in addition to factors that have previously been reported to be associated with circulating estrogen levels, including total fat mass, TT3, leptin, and ghrelin [8, 14, 20]. For the first time, we report herein that in adult female athletes with secondary amenorrhea log adiponectin concentrations, both adjusted and unadjusted for fat mass, do not predict \((p>0.05)\) estrogen exposure, and as such, fail to predict gonadal status. Similarly, other nutritionally regulated hormones, such as log leptin and ghrelin, and total fat mass, do not predict gonadal status. The strongest, and only, predictor of gonadal status was identified as TT3 (adjusted \(R^2=0.228, p=0.004\); see Table 4).
3.7 Associations with, and Predictors of, Bone Health

Using pooled data, the current study shows that both lumbar and total BMD were significantly ($p<0.05$) negatively correlated with log adiponectin (Table 3; Figure 3). Urinary E1G AUC trended ($p=0.074$) toward a significant positive association with L1-L4 BMD, but was not associated with total BMD. Using pooled data for stepwise linear regression, we entered log adiponectin, log leptin, ghrelin, insulin, E1G AUC, TT3 and BMI into two separate prediction models, one for L1-L4 BMD and one for total BMD. All of the chosen variables have been previously shown to be associated with bone health in humans [27-31]. Log adiponectin and E1G AUC collectively contributed approximately 37% to the variability of L1-L4 BMD (adjusted $R^2=0.374$, $p=0.045$; see Table 4). Total BMD was negatively predicted by log adiponectin (adjusted $R^2=0.188$, $p=0.009$; see Table 4). Although not determined to be an outlier, removal of the data point showing very high BMD and very low adiponectin (see Figure 3) did not significantly alter the predictors of bone health or the line of best fit between log adiponectin and L1-L4 BMD.

To account for the potential effects of exercise training on BMD [32], we examined bone health associations in exercising women only (ExOv and ExAmen). Both log adiponectin and log adiponectin adjusted for fat mass were significantly and negatively associated L1-L4 BMD ($r=-0.612$, $p=0.002$; $r=-0.561$, $p=0.005$, respectively) and total BMD ($r=-0.542$, $p=0.008$; $r=-0.499$, $p=0.015$, respectively). E1G AUC trended toward a positive association with L1-L4 BMD ($r=0.417$; $p=0.054$). Predictors of bone health in exercising women only were also carried out. For both L1-L4 BMD and total BMD, each model was positively predicted by log adiponectin and E1G AUC (adjusted $R^2=0.467$, $F(1,19)=10.20$, $p=0.001$; adjusted $R^2=0.333$, $F(1,29)=6.232$, $p=0.008$; respectively). Variables included in these models were the same as that used for the pooled data set.
4. DISCUSSION

The novel findings of this study are: 1) in comparison with adult eumenorrheic ovulatory sedentary and exercising women, physically active adult women with EDAA demonstrate elevated adiponectin concentrations relative to their fat mass; 2) log adiponectin adjusted for fat mass was predicted by trunkal fat mass; 3) lumbar bone health was predicted by log adiponectin and E1G AUC, while total body BMD was predicted solely by log adiponectin; and 4) the strongest predictor of gonadal status did not include secretory products of adipose tissue, namely adiponectin and leptin, but rather, nutritionally mediated metabolic hormones, specifically, TT3.

While these data are associative in nature and do not relate to causality, these findings suggest that in physically active women with EDAA: 1) elevated adiponectin and hypoestrogenemia are independently, and in combination, associated with impaired bone health; 2) circulating adiponectin is not related to nutritionally or hormonally regulated factors or gonadal status, but is inversely associated with trunkal fat mass; and 3) nutritionally mediated metabolic hormones, specifically TT3, likely play a role in mediating gonadal status via energy deficiency related mechanisms. The clinical relevance of these findings is not yet known.

4.1 Adiponectin in Amenorrheic Athletes

In the current study, we report for the first time that ExAmen demonstrate elevated log adiponectin concentrations relative to their fat mass when compared with ExOv and SedOv women, supporting an inverse relationship between body fat and adiponectin concentrations. This finding is consistent with previous studies demonstrating an inverse relationship between serum adiponectin levels and parameters of overall adiposity, such as fat mass, BMI and percent fat mass in humans [12, 13]. It is also in agreement with data showing significantly elevated adiponectin adjusted for fat mass in female anorexia nervosa patients compared with healthy age-matched adolescents [14]. In contrast, however, we report that log adiponectin concentrations that were not adjusted for fat mass were both similar between the groups and not related to whole or
regional fat mass. While this observation is not in keeping with the reported inverse association between fat mass and adiponectin [12, 13], others have similarly reported both comparable adiponectin levels and no association between total fat mass and serum adiponectin in female adolescent athletes presenting with secondary and primary amenorrhea compared with their eumenorrheic counterpart [9]. No associations of adiponectin with total fat mass have also been reported in hypoestrogenic adolescent anorexia nervosa patients [14]. Reasons for equivocal findings in the current study, and the above studies [9, 12-14] are unclear, but may be related, in part, to a number of factors, including adjustment of adiponectin concentrations relative to fat mass, differences in the adiponectin assay used (i.e., high molecular weight versus total adiponectin), the chosen population, and gonadal status.

4.2 Adiponectin and Bone

Increases in BMD above levels seen in age-matched sedentary females are notably expressed in females between 20-25 years of age participating in load bearing exercise training [32]. In the present study, however, we report that despite participation in regular load-bearing exercise training, ExAmen women demonstrate lower lumbar and total BMD in association with elevated adiponectin levels. Impaired bone health in weight-stable amenorrheic athletes has previously been shown to be associated with hypogonadism, particularly in the presence of an energy deficiency [30]. Consistent with this finding, we report here that E1G AUC was a significant contributor to our prediction model of L1-L4 BMD, and that ExAmen demonstrate significantly lower TT3 concentrations compared with SedOv and ExOv. Low TT3 levels are recognized as a marker of under-nutrition and energy deficiency [6], indicating that the hypoestrogenic physically active women in the present study were likely energy deficient. Despite these alterations, we failed to demonstrate associations between bone health and TT3. Other factors known to impact bone health were also not associated with lumbar or total BMD, including ghrelin, leptin, and insulin. This is of interest since ghrelin and insulin are known to
have stimulatory effects on osteoblastic activity [27, 28], and leptin is known to modulate bone turnover through complex central and peripheral effects [29]. In contrast, however, we report here, for the first time, that spine and total BMD are inversely associated with circulating log adiponectin concentrations in adult amenorrheic physically active women. Similarly, other studies report decreased BMD in association with increased circulating adiponectin levels in adolescent hypoestrogenic amenorrheic anorexia nervosa patients [14], and adolescent amenorrheic female athletes [9]. These findings, and that of the current study, are in keeping with the documented stimulatory affect of adiponectin on osteoclastic activity in humans [33], but are in contrast to the reported increased osteoblastic and decreased osteoclastic activity in animal models [34]. Collectively, our findings and those of others [14, 27, 29, 33, 34] underscore the complexity of the interactions between nutritionally and metabolically regulated hormones in determining bone metabolism.

4.3 Adiponectin and Gonadal Status

Among our study groups, physically active women with EDAA demonstrated the lowest estrogen exposure and the highest adiponectin concentrations compared with ovulatory groups, suggesting a possible inhibitory role of estrogen on circulating adiponectin. However, we failed to identify an association between urinary estrogen exposure over time and serum log adiponectin concentrations. In agreement with this, others similarly document no correlation between serum adiponectin and estrogen levels among premenopausal and postmenopausal women [35], and among amenorrheic and eumenorrheic adolescent athletes [9]. Lack of association between estrogen and adiponectin concentrations in the current study suggests that estrogen deficiency in amenorrheic athletes is likely reflective of menstrual status per se and that other factors coincident with amenorrhea impact serum adiponectin levels in our chosen population. Such factors could include any combination of the well documented hormonal and metabolic alterations previously reported in amenorrheic athletes, including hypoglycemia [5],
hypoinsulinemia [5, 36], hypercortisolemia [5], hypothyroidemia [36], reduced REE [37],
decreased ratio in measured versus predicted REE [10], lower leptin levels [36], and elevated
ghrelin [25] and peptide YY [10] levels. While we observed that TT3 and REE adjusted for FFM
were independently associated with gonadal status, we did not detect any relationship with
adiponectin, ghrelin, insulin, or leptin. This finding suggests that metabolic rather than
nutritionally regulated factors may mediate gonadal status in adult amenorrheic physically active
premenopausal women.

4.4 Adiponectin and Body Fat Distribution

In keeping with the well documented effect of regular physical activity on body
composition, we observed greater central and peripheral fat mass in sedentary women compared
with exercising women. Specifically, ExAmen women demonstrated significantly lower regional
and total fat mass compared with SedOv, and non-significantly lower regional and total fat mass
compared with ExOv women. Similar body composition in amenorrheic athletes has been
previously reported [6, 20, 25]. Using pooled data, trunkal fat mass, but not peripheral fat mass
or whole body fat mass, was inversely predicted by log adiponectin adjusted for fat mass. This
finding is consistent with recent in vitro evidence demonstrating that the rate of adiponectin
secretion is approximately threefold higher from visceral compared with subcutaneous fat [16].
Similarly, others have also reported an inverse association between serum adiponectin and
visceral fat [38]. These findings [16, 38], and that of the current study, supports the postulate that
distribution of body fat rather than total fat amount may be important to adiponectin metabolism.
This hypothesis awaits further investigation.

4.5 Limitations

While the primary objectives of this study were to examine serum adiponectin levels in
physically active women with EDAA and to examine whether this nutritionally regulated
hormone could predict gonadal status or bone health, the current study only examines associations, not cause and effect. In addition, our chosen method to determine predictors of adiponectin, gonadal status and bone health may not be optimal. As such, these associations and predictions should be interpreted appropriately. We also failed to examine differences between varying molecular weight adiponectin molecules, and we did not examine all possible urinary estrone conjugates. It is possible that differences exist between low, medium, high, and total molecular weight adiponectin, and between the different estrone conjugates in adult amenorrheic athletes. Finally, our study groups were of small sample size, and may have therefore affected our ability to detect true associations where present. As such, our findings should be interpreted prudently.

5. CONCLUSION

We demonstrate for the first time that total serum adiponectin levels relative to fat mass are elevated in exercising adult premenopausal women with EDAA. While this elevation does not predict gonadal status, as determined by estrogen exposure across time, increased adiponectin concentrations and estrogen exposure were independently, and in combination, associated with impaired bone health. Adiponectin relative to fat mass was also inversely associated with truncal fat mass, implying that body fat distribution rather than total body fat mass may be important in determining adiponectin concentrations. Markers of nutritionally mediated metabolic status, namely TT3, predicted estrogen exposure, suggesting that metabolic factors likely mediate gonadal status via energy deficiency related mechanisms. Although mechanisms and consequences of elevated adiponectin concentrations in amenorrheic athletes remain to be elucidated, the results of this study further characterize the unique endocrine profile of these women.
Acknowledgements: We are very grateful to the women who participated in this study.

Declaration of interest: The authors have no competing interests.

Funding: This work was supported by the Arthur Thornton Cardiopulmonary Fund, New Britain General Hospital, Connecticut.
**References**


Figure 1. Bar chart showing serum adiponectin levels adjusted for fat mass (mg/L/kg) among the study groups. * $p=0.001$ (main effect) ExAmen vs SedOv and ExOv.

Figure 2. Bar chart showing estrogen exposure across the menstrual cycle, or 30-day monitoring period, by means of daily urinary E1G area under the curve analysis for each study group. * $p=0.002$ (main effect) ExAmen vs SedOv and ExOv.

Figure 3. Scatterplot showing the relationship between lumbar spine BMD (g/cm²) and log adiponectin concentrations (ng/mL) for all groups ($r = -0.538; p=0.001; R^2=0.289$).
<table>
<thead>
<tr>
<th>Demographics</th>
<th>SedOv (n=10)</th>
<th>ExOv (n=15)</th>
<th>ExAmen (n=9)</th>
<th>P (main effect)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>27.8 ± 1.8</td>
<td>24.7 ± 0.9</td>
<td>24.0 ± 1.5</td>
<td>0.146</td>
</tr>
<tr>
<td>Age of menarche (years)</td>
<td>12.5 ± 0.4</td>
<td>12.2 ± 0.3</td>
<td>13.3 ± 0.6</td>
<td>0.177</td>
</tr>
<tr>
<td>Gynecologic age (years)</td>
<td>15.6 ± 1.8</td>
<td>12.6 ± 0.9</td>
<td>9.5 ± 1.4a</td>
<td>0.024</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>58.2 ± 2.4</td>
<td>57.5 ± 1.3</td>
<td>57.5 ± 2.0</td>
<td>0.952</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>161.6 ± 1.6</td>
<td>164.8 ± 1.3</td>
<td>165.3 ± 1.3</td>
<td>0.181</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.4 ± 0.8</td>
<td>21.3 ± 0.4</td>
<td>21.1 ± 0.7</td>
<td>0.279</td>
</tr>
<tr>
<td>Body fat total (%)</td>
<td>31.0 ± 2.2b</td>
<td>24.3 ± 1.3</td>
<td>19.9 ± 2.2</td>
<td>0.002</td>
</tr>
<tr>
<td>Body FM total (kg)</td>
<td>17.6 ± 1.9b</td>
<td>13.3 ± 0.9</td>
<td>11.2 ± 1.5</td>
<td>0.014</td>
</tr>
<tr>
<td>Trunk FM (kg)</td>
<td>8.53 ± 1.03b</td>
<td>6.2 ± 0.6</td>
<td>4.9 ± 0.7</td>
<td>0.010</td>
</tr>
<tr>
<td>Peripheral FM (kg)</td>
<td>8.4 ± 0.9</td>
<td>6.6 ± 0.4</td>
<td>5.8 ± 0.8</td>
<td>0.054</td>
</tr>
<tr>
<td>VO₂ max (ml/kg/min)</td>
<td>38.6 ± 1.3b</td>
<td>46.3 ± 1.3</td>
<td>45.4 ± 1.2</td>
<td>0.001</td>
</tr>
<tr>
<td>REE/FFM (kcal/day/kg)</td>
<td>33.4 ± 0.9</td>
<td>31.9 ± 0.7</td>
<td>28.7 ± 0.9a</td>
<td>0.002</td>
</tr>
<tr>
<td>L1-L4 BMD (g/cm²)</td>
<td>1.18 ± 0.04</td>
<td>1.28 ± 0.05</td>
<td>1.11 ± 0.04c</td>
<td>0.026</td>
</tr>
<tr>
<td>L1-L4 BMD Z-score</td>
<td>0.19 ± 0.30</td>
<td>1.05 ± 0.40</td>
<td>-0.48 ± 0.2c</td>
<td>0.015</td>
</tr>
<tr>
<td>Total BMD (g/cm²)</td>
<td>1.14 ± 0.02</td>
<td>1.20 ± 0.02</td>
<td>1.13 ± 0.02c</td>
<td>0.028</td>
</tr>
<tr>
<td>Total BMD Z-score</td>
<td>0.47 ± 0.22</td>
<td>1.24 ± 0.22d</td>
<td>0.34 ± 0.27</td>
<td>0.019</td>
</tr>
</tbody>
</table>

Values are mean ± SEM. BMI, body mass index; VO₂ max, maximal oxygen uptake; EIG, urinary estrone 3-glucuronide; AUC, area under the curve; FM, fat mass; REE, resting energy expenditure; FFM, fat free mass; BMD, bone mineral density.

a ExAmen vs. SedOv & ExOv
b SedOv vs. ExOv & ExAmen
c ExAmen vs. ExOv
d ExOv vs. ExAmen and SedOv
Table 2. Reproductive hormones and serum measures for the study groups.

<table>
<thead>
<tr>
<th></th>
<th>SedOv (n=10)</th>
<th>ExOv (n=15)</th>
<th>ExAmen (n=9)</th>
<th>P (main effect)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reproductive Hormones</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E1G AUC (ng/ml)</td>
<td>1864.9 ± 232.7</td>
<td>2047.9 ± 256.4</td>
<td>648.9 ± 160.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.002</td>
</tr>
<tr>
<td>E1G AUC/FM (ng/ml/kg)</td>
<td>126.6 ± 25.4</td>
<td>173.3 ± 23.9</td>
<td>69.9 ± 17.2&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.019</td>
</tr>
<tr>
<td><strong>Serum Measures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adiponectin (mg/L)</td>
<td>8.2 ± 0.8</td>
<td>9.4 ± 1.3</td>
<td>14.4 ± 2.7&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.028</td>
</tr>
<tr>
<td>Adiponectin/FM (mg/L/kg)</td>
<td>0.5 ± 0.1</td>
<td>0.7 ± 0.1</td>
<td>1.4 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Log Adiponectin (mg/L)</td>
<td>3.8 ± 0.1</td>
<td>3.9 ± 0.1</td>
<td>4.1 ± 0.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.056</td>
</tr>
<tr>
<td>Log Adiponectin/FM (mg/L/kg)</td>
<td>2.7 ± 0.1</td>
<td>2.8 ± 0.1</td>
<td>3.1 ± 0.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Values are mean ± SEM. BMI, body mass index; VO₂ max, maximal oxygen uptake; E1G, urinary estrone 3-glucuronide; AUC, area under the curve; FM, fat mass.

<sup>a</sup> ExAmen vs. SedOv & ExOv  
<sup>b</sup> ExAmen vs. ExOv  
<sup>c</sup> ExAmen vs. SedOv
Table 3: Bivariate correlates between hormones, body composition and bone health.*

<table>
<thead>
<tr>
<th></th>
<th>E1G AUC</th>
<th>Log Leptin</th>
<th>TT3</th>
<th>Ghrelin</th>
<th>Insulin</th>
<th>Total FM</th>
<th>Trunk FM</th>
<th>Periph. FM</th>
<th>REE/FFM</th>
<th>L1-L4 BMD</th>
<th>Total BMD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Log Adipon. (mg/L)</td>
<td>r=0.162</td>
<td>r=0.200</td>
<td>r=-0.239</td>
<td>r=0.003</td>
<td>r=0.098</td>
<td>r=0.114</td>
<td>r=-0.106</td>
<td>r=0.538</td>
<td>r=0.440</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p=0.353</td>
<td>p=0.249</td>
<td>p=0.865</td>
<td>p=0.166</td>
<td>p=0.987</td>
<td>p=0.589</td>
<td>p=0.529</td>
<td>p=0.558</td>
<td>p=0.001</td>
<td>p=0.010</td>
<td></td>
</tr>
<tr>
<td>E1G AUC (ng/ml)</td>
<td>r=0.021</td>
<td>r=0.463</td>
<td>r=-0.202</td>
<td>r=-0.003</td>
<td>r=-0.071</td>
<td>r=-0.117</td>
<td>r=-0.071</td>
<td>r=0.389</td>
<td>r=-0.320</td>
<td>r=0.182</td>
<td></td>
</tr>
<tr>
<td></td>
<td>p=0.906</td>
<td>p=0.007</td>
<td>p=0.593</td>
<td>p=0.985</td>
<td>p=0.705</td>
<td>p=0.531</td>
<td>p=0.705</td>
<td>p=0.030</td>
<td>p=0.074</td>
<td>p=0.328</td>
<td></td>
</tr>
<tr>
<td>Log Leptin (ng/ml)</td>
<td>-</td>
<td>r=0.309</td>
<td>r=-0.097</td>
<td>r=-0.003</td>
<td>r=-0.071</td>
<td>r=-0.117</td>
<td>r=-0.071</td>
<td>r=0.389</td>
<td>r=-0.320</td>
<td>r=0.182</td>
<td></td>
</tr>
<tr>
<td></td>
<td>p=0.070</td>
<td>p=0.245</td>
<td>p=0.819</td>
<td>p=0.985</td>
<td>p=0.705</td>
<td>p=0.531</td>
<td>p=0.705</td>
<td>p=0.030</td>
<td>p=0.074</td>
<td>p=0.328</td>
<td></td>
</tr>
<tr>
<td>TT3 (ng/dl)</td>
<td>r=-0.242</td>
<td>r=0.277</td>
<td>r=0.743</td>
<td>r=0.681</td>
<td>r=0.731</td>
<td>r=0.479</td>
<td>r=-0.105</td>
<td>r=-0.113</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p=0.161</td>
<td>p=0.108</td>
<td>p=0.046</td>
<td>p=0.082</td>
<td>p=0.040</td>
<td>p=0.019</td>
<td>p=0.963</td>
<td>p=0.636</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ghrelin (pg/ml)</td>
<td>-</td>
<td>r=-0.106</td>
<td>r=-0.260</td>
<td>r=-0.310</td>
<td>r=-0.017</td>
<td>r=-0.047</td>
<td>r=0.029</td>
<td>r=0.145</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p=0.544</td>
<td>p=0.143</td>
<td>p=0.079</td>
<td>p=0.337</td>
<td>p=0.017</td>
<td>p=0.869</td>
<td>p=0.422</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin (uIU/ml)</td>
<td>-</td>
<td>r=0.056</td>
<td>r=0.096</td>
<td>r=0.001</td>
<td>r=0.281</td>
<td>r=0.247</td>
<td>r=0.121</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p=0.756</td>
<td>p=0.597</td>
<td>p=0.997</td>
<td>p=0.113</td>
<td>p=0.158</td>
<td>p=0.502</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total FM (kg)</td>
<td>-</td>
<td>r=0.944</td>
<td>r=0.955</td>
<td>r=0.524</td>
<td>r=0.138</td>
<td>r=0.004</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p=0.000</td>
<td>p=0.000</td>
<td>p=0.002</td>
<td>p=0.443</td>
<td>p=0.983</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trunk FM (kg)</td>
<td>-</td>
<td>r=0.804</td>
<td>r=0.595</td>
<td>r=0.133</td>
<td>r=0.022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p=0.000</td>
<td>p=0.000</td>
<td>p=0.460</td>
<td>p=0.904</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral FM (kg)</td>
<td>-</td>
<td>r=0.603</td>
<td>r=-0.126</td>
<td>r=0.011</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p=0.000</td>
<td>p=0.486</td>
<td>p=0.949</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REE/FFM (kcal/day/kg)</td>
<td>-</td>
<td></td>
<td></td>
<td>r=0.092</td>
<td>r=-0.191</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p=0.612</td>
<td>p=0.286</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L1-L4 BMD (g/cm2)</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td>r=0.902</td>
<td>p=0.000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adipon, adiponectin; EIG, urinary estrone 3-glucuronide; AUC, area under the curve; TT3, total triiodothyronine; FM, fat mass; Periph, peripheral; REE, resting energy expenditure; FFM, fat free mass; BMD, bone mineral density.

* Using pooled data (all women, n=34). Significant correlations are bolded.
Table 4. Regression analysis (stepwise regression) of predictors of adiponectin*, estrogen exposure, and bone mineral density.

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>SE</th>
<th>β</th>
<th>F ratio</th>
<th>R²</th>
<th>R² adj</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adiponectin*/FFM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intercept</td>
<td>3.273</td>
<td>0.093</td>
<td></td>
<td></td>
<td>23.538</td>
<td>0.432</td>
<td>0.413</td>
</tr>
<tr>
<td>Trunk Fat Mass</td>
<td>-0.065</td>
<td>0.013</td>
<td>-0.657</td>
<td></td>
<td>23.538</td>
<td>0.432</td>
<td>0.413</td>
</tr>
<tr>
<td>Estrogen Exposure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9.885</td>
<td>0.228</td>
<td>0.254</td>
</tr>
<tr>
<td>Intercept</td>
<td>-10138.32</td>
<td>3769.86</td>
<td></td>
<td></td>
<td>9.885</td>
<td>0.228</td>
<td>0.254</td>
</tr>
<tr>
<td>TT3</td>
<td>5920.38</td>
<td>1883.09</td>
<td>0.504</td>
<td></td>
<td>9.885</td>
<td>0.228</td>
<td>0.254</td>
</tr>
<tr>
<td>Total BMD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7.948</td>
<td>0.188</td>
<td>0.215</td>
</tr>
<tr>
<td>Intercept</td>
<td>1.803</td>
<td>0.227</td>
<td></td>
<td></td>
<td>7.948</td>
<td>0.188</td>
<td>0.215</td>
</tr>
<tr>
<td>Adiponectin*</td>
<td>-0.161</td>
<td>0.057</td>
<td>-0.464</td>
<td></td>
<td>7.948</td>
<td>0.188</td>
<td>0.215</td>
</tr>
<tr>
<td>L1-L4 BMD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>13.683</td>
<td>0.297</td>
<td>0.321</td>
</tr>
<tr>
<td>Intercept</td>
<td>2.728</td>
<td>0.414</td>
<td></td>
<td></td>
<td>13.683</td>
<td>0.297</td>
<td>0.321</td>
</tr>
<tr>
<td>Adiponectin*</td>
<td>-0.406</td>
<td>0.104</td>
<td>-0.565</td>
<td></td>
<td>13.683</td>
<td>0.297</td>
<td>0.321</td>
</tr>
<tr>
<td>E1G AUC</td>
<td>0.048</td>
<td>0.000</td>
<td>0.304</td>
<td></td>
<td>9.856</td>
<td>0.413</td>
<td>0.374</td>
</tr>
</tbody>
</table>

All women, n=34.
* signifies log adjusted data
Figure 1

SedOv  ExOv  ExAmen

Menstrual and Ovulatory Status

Adiponectin (mg/L/kg)
Figure 2

![Bar graph showing Estrogen AUC (ng/ml) for different Menstrual and Ovulatory Status categories: SedOv, ExOv, and ExAmen. The graph indicates a statistically significant difference (*).](image)
Figure 3

![Graph showing Adiponectin Log 10 (mg/mL) vs. L1-L4 BMD (g/cm sq). The graph includes data points for SedOv, ExOv, ExMen, and a fit line. The coefficient of determination, $R^2=0.289$, is indicated.](image-url)